Literature DB >> 28647584

Transforaminal lumbar interbody fusion (TLIF) versus posterior lumbar interbody fusion (PLIF) in lumbar spondylolisthesis: a systematic review and meta-analysis.

Suzanne L de Kunder1, Sander M J van Kuijk2, Kim Rijkers3, Inge J M H Caelers4, Wouter L W van Hemert5, Rob A de Bie6, Henk van Santbrink7.   

Abstract

BACKGROUND CONTEXT: Transforaminal lumbar interbody fusion (TLIF) and posterior lumbar interbody fusion (PLIF) are both frequently used as a surgical treatment for lumbar spondylolisthesis. Because of the unilateral transforaminal route to the intervertebral space used in TLIF, as opposed to the bilateral route used in PLIF, TLIF could be associated with fewer complications, shorter duration of surgery, and less blood loss, whereas the effectiveness of both techniques on back or leg pain is equal.
PURPOSE: The objective of this study was to compare the effectiveness of both TLIF and PLIF in reducing disability, and to compare the intra- and postoperative complications of both techniques in patients with lumbar spondylolisthesis. STUDY DESIGN/
SETTING: A systematic literature review and meta-analysis were carried out.
METHODS: We conducted a Medline (using PubMed), Embase (using Ovid), Cochrane Library, Current Controlled Trials, ClinicalTrials.gov and NHS Centre for Review and Dissemination search for studies reporting TLIF, PLIF, lumbar spondylolisthesis and disability, pain, complications, duration of surgery, and estimated blood loss. A meta-analysis was performed to compute pooled estimates of the differences between TLIF and PLIF. Forest plots were constructed for each analysis group.
RESULTS: A total of 192 studies were identified; nine studies were included (one randomized controlled trial and eight case series), including 990 patients (450 TLIF and 540 PLIF). The pooled mean difference in postoperative Oswestry Disability Index (ODI) scores between TLIF and PLIF was -3.46 (95% confidence interval [CI] -4.72 to -2.20, p≤.001). The pooled mean difference in the postoperative VAS scores was -0.05 (95% CI -0.18 to 0.09, p=.480). The overall complication rate was 8.7% (range 0%-25%) for TLIF and 17.0% (range 4.7-28.8%) for PLIF; the pooled odds ratio was 0.47 (95% CI 0.28-0.81, p=.006). The average duration of surgery was 169 minutes for TLIF and 190 minutes for PLIF (mean difference -20.1, 95% CI -33.5 to -6.6, p=.003). The estimated blood loss was 350 mL for TLIF and 418 mL for PLIF (mean difference -43.9 mL, 95% CI -71.2 to -16.6, p=.002).
CONCLUSIONS: TLIF has advantages over PLIF in the complication rate, blood loss, and operation duration. The clinical outcome is similar, with a slightly lower postoperative ODI score for TLIF.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Complications; Disability; Lumbar spondylolisthesis; PLIF; Spinal fusion; TLIF

Mesh:

Year:  2017        PMID: 28647584     DOI: 10.1016/j.spinee.2017.06.018

Source DB:  PubMed          Journal:  Spine J        ISSN: 1529-9430            Impact factor:   4.166


  43 in total

1.  Differences in the interbody bone graft area and fusion rate between minimally invasive and traditional open transforaminal lumbar interbody fusion: a retrospective short-term image analysis.

Authors:  Yu-Cheng Yao; Hsi-Hsien Lin; Po-Hsin Chou; Shih-Tien Wang; Ming-Chau Chang
Journal:  Eur Spine J       Date:  2019-06-07       Impact factor: 3.134

2.  Posterior stabilization with polyetheretherketone (PEEK) rods and transforaminal lumbar interbody fusion (TLIF) with titanium rods for single-level lumbar spine degenerative disease in patients above 70 years of age.

Authors:  M Kamenova; E Li; J Soleman; O Fiebig; A Mehrkens; S Schaeren
Journal:  Arch Orthop Trauma Surg       Date:  2022-05-05       Impact factor: 3.067

3.  Transforaminal lumbar interbody fusion with a silicon nitride cage demonstrates early radiographic fusion.

Authors:  Mitchell T Gray; Kyle P Davis; Bryan J McEntire; B Sonny Bal; Micah W Smith
Journal:  J Spine Surg       Date:  2022-03

4.  Risk factors for cage subsidence and clinical outcomes after transforaminal and posterior lumbar interbody fusion.

Authors:  Tiago Amorim-Barbosa; Catarina Pereira; Diogo Catelas; Cláudia Rodrigues; Paulo Costa; Ricardo Rodrigues-Pinto; Pedro Neves
Journal:  Eur J Orthop Surg Traumatol       Date:  2021-08-31

5.  History and Evolution of the Minimally Invasive Transforaminal Lumbar Interbody Fusion.

Authors:  Michael C Prabhu; Kevin C Jacob; Madhav R Patel; Hanna Pawlowski; Nisheka N Vanjani; Kern Singh
Journal:  Neurospine       Date:  2022-09-30

6.  [Current status and progress of minimally invasive percutaneous endoscopic lumbar interbody fusion].

Authors:  Xian Chang; Changqing Li
Journal:  Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi       Date:  2022-06-15

7.  Comparison of Transforaminal Lumbar Interbody Fusion Using the Boomerang-Shaped Cage with Traditional Posterior Lumbar Interbody Fusion for Lumbar Spondylolisthesis.

Authors:  Yohei Ishihara; Masutaro Morishita; Jiro Miyaki; Koji Kanzaki; Tomoaki Toyone
Journal:  Spine Surg Relat Res       Date:  2018-07-25

8.  [Comparison of minimally invasive transforaminal lumbar interbody fusion between two approaches in treatment of single-segment lumbar spinal stenosis].

Authors:  Rui Zhong; Runsheng Wang; Jianheng Liu; Zhenchuan Han; Wei Jiang; Qingzu Liu; Keya Mao
Journal:  Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi       Date:  2019-07-15

9.  [Comparative study on effectiveness of modified-transforaminal lumbar interbody fusion and posterior lumbar interbody fusion surgery in treatment of mild to moderate lumbar spondylolisthesis in middle-aged and elderly patients].

Authors:  Zhijie Yang; Bo Liu; Haiyang Lan; He Ye; Jie Chen; Huiqiang Xia; Ye Zhang; Fei Han
Journal:  Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi       Date:  2020-05-15

10.  Expandable spacers provide better functional outcomes than static spacers in minimally invasive transforaminal lumbar interbody fusion.

Authors:  M Adam Kremer; Jefferson Alferink; Stacie Wynsma; Torrey Shirk; Charles Ledonio
Journal:  J Spine Surg       Date:  2019-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.